Finance Press

The title of the subsidiary to 63.17% from the financial FIME stock market jumps to 9.6 euro, appreciated by 3.96%. According to analysts Recordati remains a buy opportunity, as it is the only Italian pharmaceutical company with substantial investments in research and development. E ’scheduled for May 10th presentation in Milan of the company, which will be commented during the economic and financial data for the first quarter of 2000. The title has scored YTD gain of 17.6%.

Related posts

• Moscow: “Exchanges low coupon adjustments” (0)
• A. CROUZAT: “France Telecom and ‘well positioned’ (0)
• Tiscali, which scenario is the future? (0)
• Rome relives the nightmare of the stock exchange yesterday at San Siro (0)
• Resists Lagardere because of good results 2000 (0)